Skip to main content

Table 3 Promter Hypermethylation and cervical cancer survival

From: Frequent Promoter Methylation of CDH1, DAPK, RARB, and HIC1 Genes in Carcinoma of Cervix Uteri: Its Relationship to Clinical Outcome

  

Alive

Dead

Hazard Ratio§

95%CI

Total loci

0

9

2

1.00

–

 

1

6

9

0.75

0.14–4.00

 

2

13

19

1.04

0.20–5.50

 

≥3

11

13

1.07

0.19–5.92

CDH1

+

18

27

0.69

0.29–1.63

 

-

21

16

1.00

–

DAPK

+

19

18

0.53

0.23–1.19

 

-

20

25

1.00

–

RARB

+

8

16

1.66

0.80–3.46

 

-

31

27

1.00

–

HIC1

+

7

8

1.67

0.69–4.04

 

-

32

35

1.00

–

FHIT

+

3

6

1.18

0.38–3.66

 

-

36

37

1.00

–

RASSF1A

+

5

1

2.02

0.16–25.08

 

-

34

42

1.00

–

APC

+

4

5

0.70

0.21–2.41

 

-

35

38

1.00

–

CDKN2A

+

2

5

1.64

0.51–5.26

 

-

37

38

1.00

–

MGMT

+

0

4

2.30

0.46–11.45

 

-

39

39

1.00

–

BRCA1

+

0

5

3.05

0.72–12.93

 

-

39

38

1.00

–

  1. Adjusted for age (continuous), treatment (3 groups), tumor size (binary), stage (3 groups) and HPV type (4 groups)